Observe Medical ASA, December 21, 2020: Following the acquisition by Observe
Medical of Sylak AB on October 30, the team and product portfolio are now
successfully integrated into Observe Medical and in full operations, with focus
on the Swedish market.

Observe Medical is currently launching Sippi® automated digital urine meter in
selected markets in Europe, with the near-term focus of accelerating Sippi
clinical use in Nordics. Therefore, the access to Sippi target customers is key,
specifically important during the current pandemic, since the access to
healthcare professionals is restricted, especially at ICUs and other departments
at hospitals. The portfolio added through the acquisition of Sylak consists of a
broad range of hospital products within urine measurement, anaesthesia/ICU and
wound care. The product range is complimentary to Sippi, providing access and
enabling sales calls with Sippi target customers. It has already generated
several customer requests for Sippi testing and implementation during early 2021
at key hospitals. In addition, the integration has brought significant synergies
by enhancing Observe Medical sales operational capabilities, for example in
tender management, logistics and warehousing.

The Observe Medical sales team is further expanding with a new Nordic key
account manager (KAM), joining in January 2021. The new KAM, like the colleagues
in the sales team, has a background as a specialist nurse, a highly relevant
competence and experience for driving Sippi clinical use as well as for the
sales growth of the full Observe Medical portfolio. In the coming period the
sales operations will further expand with direct sales team on the ground in the
Nordics. With the strong international experience in the sales team, they are
also key in transferring the Nordic Sippi references and learnings when
enhancing our international distributor network.

"The pandemic is highlighting key clinical challenges, not the least at ICUs and
other hospital departments. Our sales team has excellent and long-standing
relations with the departments at major hospitals. It is highly motivating for
me and my team to be fully on board Observe Medical, and to continue helping our
customers, the caregivers, in their daily work with patients. Sippi has the same
target customers as the rest of our portfolio and several of the products are
directly synergistic and can be bundled with Sippi". I expect this to further
drive Sippi clinical use and portfolio sales growth" says Anders Nachtweij, Head
of Sales, Observe Medical, formerly General Manager of Sylak.

"We are excited to move into 2021 with full speed and force, and further
accelerate Sippi clinical use and portfolio sales growth in the Nordics - lead
by Anders Nachtweij, our new Head of Sales, and his team. The integration of the
Sylak team represents a boost of momentum and energy in a critical phase of the
Sippi commercialization and for Observe Medical," Björn Larsson, CEO Observe
Medical" concludes.

For further information, please contact:

Björn Larsson, CEO, mobile: +46 76 620 17 25 E-mail:
bjorn.larsson@observemedical.com

About Observe Medical

Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anaesthesiology/ICUs and wound care,  in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems, and hinders bacterial migration that can lead to urinary infections
(Sippcoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.